Blinatumomab is the first in its class bispecific T-cell engager monoclonal antibody, which binds to CD19 expressed on B-cells and CD3 expressed on T-cells, resulting in lysis of CD19-positive cells common in B-cell malignancies. Blinatumomab is Food and Drug Administration (FDA) approved for the treatment of adults and children with relapsed/refractory or minimal residual disease (MRD) positive precursor B-cell ALL (B-ALL). Despite impressive efficacy for the approved indications and favorable toxicity profile compared to standard-of-care chemotherapy, blinatumomab presents unique health-system challenges related to preparation, administration, toxicity monitoring and medication error prevention. Blinatumomab delivery also offers plethora of opportunities for interdisciplinary planning and collaboration. The purpose of this paper is to discuss practical considerations for safe blinatumomab delivery from the pharmacy and nursing perspectives.
HungerSPMullighanCG.Acute lymphoblastic leukemia in children. N Engl J Med2015;
373: 1541–1552.
2.
Rodriguez-GalindoCFriedrichPAlcasabasP, et al.
Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol2015;
33: 3065–3073.
3.
SEER Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, https://seer.cancer.gov/explorer/ (accessed 4 September 2020).
4.
RheingoldSRJiLXuX, et al.
Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a children’s oncology group (COG) study. JCO2019;
37: 10008–10008.
5.
NguyenKDevidasMChengSC, et al.; Children's Oncology Group.
Factors influencing survival after relapse from acute lymphoblastic leukemia: a children's oncology group study. Leukemia2008;
22: 2142–2150.
6.
GökbugetNZugmaierGKlingerM, et al.
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica2017;
102: e132–e135. e5.
7.
KantarjianHSteinAGökbugetN, et al.
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med2017;
376: 836–847.
8.
ToppMSGökbugetNSteinAS, et al.
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol2015;
16: 57–66.
9.
von StackelbergALocatelliFZugmaierG, et al.
Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. JCO2016;
34: 4381–4389.
10.
BrownPAJiLXuX, et al.
A randomized phase 3 trial of blinatumomab Vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children's oncology group study AALL1331. Blood2019;
134: LBA-1–LBA.
United States Pharmacopeial Compounding Chapter USP <797>: guidebook to pharmaceutical compounding: sterile preparations. Rockville, MD.: United States Pharmacopeia Convention, 2008.
ConnorTHMBDeBordDGTroutDB, et al.; NIOSH. NIOSH list of hazardous drugs in healthcare settings. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH), 2020.
InwoodS.An exploration of the past, present and future of catheter securement. Br J Nurs2014;
23: S26–7.
20.
McNicholLLundCRosenT, et al.
Medical adhesives and patient safety: state of the science: consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. J Wound Ostomy Continence Nurs2013;
40: 365–380. quiz E1–2.
21.
GoossensGA.Flushing and locking of venous catheters: available evidence and evidence deficit. Nurs Res Pract2015;
2015: 985686.
22.
O'GradyNPAlexanderMBurnsLA, et al.; Healthcare Infection Control Practices Advisory Committee.
Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control2011;
39: S1–34.
23.
UllmanAJCookeMLGilliesD, et al.
Optimal timing for intravascular administration set replacement. Cochrane Database Syst Rev2013;
2013: Cd003588.
24.
TeacheyDTRheingoldSRMaudeSL, et al.
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood2013;
121: 5154–5157.
25.
KlingerMBrandlCZugmaierG, et al.
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood2012;
119: 6226–6233.
26.
LeeDWGardnerRPorterDL, et al.
Current concepts in the diagnosis and management of cytokine release syndrome. Blood2014;
124: 188–195.
27.
LeeDWSantomassoBDLockeFL, et al.
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant2019;
25: 625–638.
28.
NeelapuSSTummalaSKebriaeiP, et al.
Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol2018;
15: 47–62.
MaudeSLBarrettDTeacheyDTGruppSA.Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J2014;
20: 119–122.
32.
SteinASSchillerGBenjaminR, et al.
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol2019;
98: 159–167.
33.
ChenJNgoDRosenthalJ.Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with Central nervous system disease. J Oncol Pharm Pract2019;
25: 2027–2030.
34.
Blincyto® (blinatumomab) Risk Evaluation and Mitigation Strategy (REMS), www.blincytorems.com (accessed 24 July 2020).
